TP53 and Li-Fraumeni syndrome: Women carriers of germline TP53 mutations and diagnosed with Li-Fraumeni Syndrome and a SNP-309 G residue develop breast cancers with a mean age of 29 years, whereas women with a SNP-309 T-residue develop breast cancers with a mean age of 39 years (p = 0.01) [55].